Letiexhe, Michel ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Mathieu, C.
Nobels, F. R.
Rottiers, R.
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson J, The Benelux-UK Insulin Lispro Study Group. Reduced frequency of severe hypoglycaemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabetes Care 1997; 20: 1827-1832.
Anderson JH, Brunelle Rl, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, DiMarchi R and The Multicenter Insulin Lispro Study Group. Reduction of postprandial hyperglycaemia and frequency of hypoglycaemia in IDDM patients on insulin analog treatment. Diabetes 1997; 46: 265-270.
Anderson JH, Brunelle Rl, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R and The Multicenter Insulin Lispro Study Group. Improved mealtime treatment of diabetes mellitus using insulin analogue. Clin Ther 1997; 19: 62-72.
Anderson JH, Brunelle Rl, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycaemia in NIDDM patients. Arch Intern Med 1997; 157: 1249-1255.
Vignati L, Anderson JH Jr, Iversen PW. Efficacy of insulin lispro in combination with NPH human insulin, given twice per day in IDDM and NIDDM patients. Clin Ther 1997; 19: 62-72.
Holcombe J, Zalani S, Arora V, Headlee S, Gill A. Insulin lispro (LP) results in less nocturnal hypoglycaemia compared with regular human insulin in adolescents with type I diabetes. Diabetes 1997; 46 (Suppl 1): 103A.
Holcombe J, Zalani S, Arora V, Gill A, Headlee S. Patient preference for insulin lispro versus Humulin R in adolescents with type I diabetes. Diabetologia 1997; 40 (Suppl 1): A343.
Koivisto VA. The human insulin analogue - Insulin lispro. Ann. Med. 1998;30:260-266.
De Leeuw I, Rutters A, Schmitt H et al. [Lys(B28),Pro(B29)] human insulin (LysPro): Patients treated with LysPro vs. human regular insulin: Quality of Life assessment (QOL). 15th International Diabetes Federation Congress 1994; 253.
Kotsanos JG, Vignati L, Huster W et al. Health-related quality-of-life results from multinational clinical trials of insulin lispro: assessing benefits of a new diabetes therapy. Diabetes Care 1997; 20: 948-958.
Del Sindaco P, Ciofetta M, Lalli C, et al. Use of the short acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection meal. Diabetic Med. 1998; 15: 592-600.
Lalli C, Ciofetta M, Del Sindaco P et al. Lispro in intensive management of IDDM: one year experience. Diabetes 1998; 47, suppl.1, 397.
Colombel A, Murat A, Anton B, et al. An intensive insulin therapy regimen using lispro + multiple NPH improves HbA1c and reduces blood glucose variability. Diabetes 1998; 47 (Suppl1): 1396.
Jansson P-A, Ebeling P, Smith U et al. Improved glycaemic control can be better maintained with insulin lispro than with human regular insulin. Diab. Nutr. Metab. 1998; 11: 194-199.
Desmet M, Rutters A, Schmitt H, Satter E. [Lys(B28),Pro(B29)] human insulin (LysPro): patients treated with LysPro vs. human regular insulin: quality of life assessment. Diabetes 1994; 43 (Suppl 1): 167A.
Letiexhe MR, Rutters A, Schmitt H. [Lys(B28),Pro(B29)] human insulin (LysPro): patients treated with LysPro vs. human regular insulin: quality of life assessment. Diabetologia 1994; 37 (Suppl 1): A118.
Hermans MP (unpublished data).
De Schepper (personal communication).
Zinman B, Ross S, Campos RV, Strack T, for the Canadian Lispro Study Group. Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. Diabetes Care 22: 603-607, 1999.
